KTET Answer Key

Celldex Therapeutics is in the biotechnology industry and is in the healthcare sector. The company CEO is Anthony S. Marucci. Celldex Therapeutics Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.

Previous Intraday Performance:

The CLDX shares had a previous change of -5.06% which opened at 4.30 and closed at 4.13. It moved to an intraday high of 4.38 and a low of 4.10.

SeekingAlpha:  Microcaps dominate midday movers

Historical Performance:

Over the last five trading days, CLDX shares returned -15.02% and in the past 30 trading days it returned -18.22%. Over three months, it changed 5.69%. In one year it has changed -63.82% and within that year its 52-week high was 15.90 and its 52-week low was 2.75. CLDX stock is 50.46% above its 52 Week Low.

Our calculations result in a 200 day moving average of 5.72 and a 50 day moving average of 5.35. Right now, CLDX stock is trading -27.81% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Microcaps dominate midday movers


The company has a market cap of $51.4m with 12.4m shares outstanding and a float of 5.8m shares. Trading volume was 312,934 shares and has experienced an average volume of 474,447 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Celldex Therapeutics was -15.24 which ended on 31st of December 2018. Based on 1 analyst estimate, the estimated EPS for the next quarter is -1.14.

The next earnings report will be: 05-02-2019

The long-term trend of the EPS is a vital number as it helps understand the future potential of Celldex Therapeutics; the EPS growth rate, as it is typically called, is usually expressed as a percentage, which at this time is hard to estimate, but revenue growth has been -38.60% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 4.60% of insider ownership and 37.50% of institutional ownership.

I calculated the beta to be 4.25

Business Wire:  Second Sight Medical Products, Inc. Presents Positive Interim Results at the Fifth Annual BRAIN Initiative® Investigators Meeting

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -83.89%, return on assets is -64.14%, price-to-sales is 9.89 and price-to-book is 0.44.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 6  : Financial Safety Result
 0  : Past Performance Result
 1  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here